BioCatalyst

KRYS — Krystal Biotech, Inc. catalysts

3 verified catalyst event(s) for Krystal Biotech, Inc. (ticker KRYS). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-12-01 — A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 27d
ESTIMATED
 READOUT
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic
Phase 1/2 · Neurotrophic Keratitis
 KRYS Krystal Biotech, Inc. KB801 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
 READOUT
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo
Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
 KRYS Krystal Biotech, Inc. KB803 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-02 (month)
in 3mo
ESTIMATED
 READOUT
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies A
Phase 1/2 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic
 KRYS Krystal Biotech, Inc. KB707, Pembrolizumab (KEYTRUDA®), Chemot ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.